Participant flow

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma · Source last updated 2024-10-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent

   id

   FG000

   title

   Zanubrutinib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         13

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Physician Decision

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         68

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         51

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         17

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The study was composed of an initial screening phase (up to 35 days), a single-arm treatment phase, and a follow-up phase. A total of 38 participants rolled over to BGB-3111-LTE1 (NCT04170283) after study completion.

recruitment Details

This study was conducted at 31 study centers in 9 countries.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice